Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nucana Plc ADR (NQ: NCNA )

1.240 -0.010 (-0.80%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 85,619
Open 1.250
Bid (Size) 1.240 (1)
Ask (Size) 1.260 (3)
Prev. Close 1.250
Today's Range 1.230 - 1.270
52wk Range 1.225 - 19.41
Shares Outstanding 52,372,887
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
From NuCana plc
Via GlobeNewswire

Performance

YTD
-84.34%
-84.34%
1 Month
-20.00%
-20.00%
3 Month
-59.34%
-59.34%
6 Month
-63.10%
-63.10%
1 Year
-87.46%
-87.46%

More News

Read More
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
From NuCana plc
Via GlobeNewswire
NCNA Stock Earnings: NuCana Beats EPS for Q2 2024
Via InvestorPlace
NCNA Stock Earnings: NuCana Beats EPS for Q1 2024
Via InvestorPlace
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September
Via Benzinga
Topics Stocks
Exposures US Equities
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
Via Benzinga
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
From NuCana plc
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
NuCana Stock Plunges On Colorectal Combo Therapy Trial Setback, Ends Mid-Stage Study After Disappointing Data
Via Benzinga
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
From NuCana plc
Via GlobeNewswire
Why Bit Digital Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
NuCana to Present at the Jefferies Global Healthcare Conference
From NuCana plc
Via GlobeNewswire
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
From NuCana plc
Via GlobeNewswire
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
From NuCana plc
Via GlobeNewswire
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
From NuCana plc
Via GlobeNewswire
NuCana Announces Completion of ADS Ratio Change
From NuCana plc
Via GlobeNewswire
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
From NuCana plc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.